Optimization of LC method for the quantification of doxorubicin in plasma and urine samples in view of pharmacokinetic, biomedical and drug monitoring therapy studies

    loading  Checking for direct PDF access through Ovid


HIGHLIGHTSVarious approaches of sample procedure preparations for doxorubicin from plasma and urine were performed and compared.Simple, sensitive and cost-effective LC-FL method for doxorubicin quantification in biological fluids was developed and validated.The developed LC-FL methodology was successfully applied to a monitoring of doxorubicin in pediatric cancer patients.The exposure of hospital personnel to doxorubicin in plasma and urine samples was evaluated in clinical practice.The LC-FL method can be considered as interesting tool with respect to previously reported LC and CE methodologies.A simple, rapid, reliable and sensitive method based on liquid chromatography with fluorescence detection (LC-FL) for the quantification of doxorubicin (DOX) in human plasma and urine samples was developed. The assay was carried out after the solid-phase extraction procedure (SPE) with hydrophilic-lipophilic balance (HLB) cartridges, and with daunorubicin hydrochloride (DAU) used as the internal standard. Chromatographic separation was performed on a Discovery HS C18 column in isocratic elution mode, and the detection of the analytes set at excitation and emission wavelengths of 487 and 555nm, respectively. The developed LC-FL method has been validated for accuracy, precision, selectivity, linearity, recovery and stability. The limits of detection and quantification for DOX were 0.5 and 1ng/mL in both biological fluids, respectively. Linearity was confirmed in the range of 1–1000ng/mL and 0.001–25μg/mL in plasma and urine samples, respectively, with a correlation coefficient greater than 0.9994. The proposed LC-FL method is selective, precise and accurate, and has been successfully applied for drug monitoring in pediatric cancer patients treated with DOX as a component of OEPA (Oncovin (Vincristine)-Etoposide-Prednisone-Adriamycin) and IOA (Ifosfamide-Oncovin-Adriamycin) chemotherapeutic schemes. Moreover, real exposure of hospital personnel to the anthracycline drugs in plasma and urine was evaluated in clinical practice.

    loading  Loading Related Articles